CagriSema Weight Loss Calculator
Estimate your potential weight loss based on REDEFINE 1 clinical trial data
Medical Disclaimer: This tool provides general educational estimates. Always consult your prescribing physician or healthcare provider before making medication changes or interpreting results from population-based models.
Frequently Asked Questions
In the REDEFINE 1 clinical trial (N=3,417), participants taking CagriSema lost an average of 20.4% of their body weight over 68 weeks. For a 220 lb person, that translates to roughly 45 lbs. However, individual results ranged widely. Results depend on starting weight, adherence, diet, and exercise habits.
CagriSema combines two active ingredients — cagrilintide (an amylin analog) and semaglutide (a GLP-1 agonist) — in a single weekly injection. Ozempic contains only semaglutide. By targeting both the GLP-1 and amylin pathways, CagriSema produces approximately 20.4% weight loss vs. ~8-15% for semaglutide alone.
In cross-trial comparisons, tirzepatide (Mounjaro/Zepbound) showed ~22.5% mean weight loss at 72 weeks, while CagriSema showed ~20.4% at 68 weeks. These numbers are not directly comparable due to different trial populations. A head-to-head trial would be needed.
As of early 2026, Novo Nordisk has submitted CagriSema for FDA review. An FDA decision is expected in 2026. Pricing has not been announced but is expected to be similar to or higher than Wegovy (~$1,300/month).
Yes. The weight loss projections are derived from the REDEFINE 1 clinical trial (Lingvay et al., New England Journal of Medicine, 2025, N=3,417). This phase 3 trial was randomized, double-blind, and conducted at multiple sites internationally.
Sources
- Lingvay I, Cheng AY, Engberg S, et al. CagriSema Once Weekly in Obesity. N Engl J Med. 2025. Link
- Novo Nordisk. REDEFINE 1 Phase 3 Trial Results. ClinicalTrials.gov Identifier: NCT05567796. Link
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. Link
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. Link
Methodology
This calculator projects weight loss by applying mean percentage weight loss values from the REDEFINE 1 phase 3 clinical trial (Lingvay et al., NEJM 2025; N=3,417) to the user's starting body weight. The trial's primary endpoint at 68 weeks showed 20.4% mean body weight loss with CagriSema versus 5.8% with semaglutide 2.4 mg alone and 3.3% with placebo. Intermediate time points (16, 32, and 48 weeks) are interpolated from the published weight loss trajectory curve.
These projections reflect population averages from a controlled clinical trial combining CagriSema with a reduced-calorie diet and increased physical activity. Individual results vary significantly. CagriSema is not yet FDA-approved as of early 2026.
CagriSema (cagrilintide + semaglutide) produced 20.4% mean body weight loss at 68 weeks in the REDEFINE 1 trial (N=3,417). It combines amylin and GLP-1 pathways in a single weekly injection. Comparison: tirzepatide ~22.5% at 72 weeks (SURMOUNT-1), semaglutide 2.4 mg ~16% at 68 weeks (STEP 1). Not yet FDA-approved as of early 2026.
What else do you want to know?
Ask Pulse anything.